Roberts, C. A. | Search bioRxiv

bioRxiv2026

COSMOS: A FAIR-aligned infrastructure for clinical trial data validation, warehousing, and interactive discovery

1.SummaryThe Clinical Omics System for Metadata and Outcome Storage (COSMOS) is an open-source, FAIR- and GCP aligned clinical trial unit (CTU) infrastructure designed to streamline the transition of academic clinical and multi-omic trial datasets into curated, analysis-ready repositories within Secure Data Environments (SDEs). By integrating an automated Data Quality and Data Validation (DQ&DV) "Trust Layer" with a relational Structured Query Language (SQL) schema, COSMOS enables programmatic and interactive data access via R Shiny applications. Dynamic integration of omics and clinical data is achieved through analytical data structures (e.g. ExpressionSet objects) linked via relational database identifiers. This lowers technical barriers for researchers and promotes governed data reuse and secondary discovery. Availability and ImplementationCOSMOS is freely available under the GPL-3.0 license at https://github.com/at2e19/SCTU_COSMOS_DQDV_Shiny Supplementary information: Supplementary data are available at Bioinformatics online.

bioinformatics↗

bioRxiv2018

Master regulators of genetic interaction networks mediating statin drug response in Saccharomyces cerevisiae vary with genetic background

Determination of genetic interaction networks (GINs) surrounding drug targets identifies buffering genes and provides molecular insight into drug response in individuals. Here we used backcross methodology to create Saccharomyces cerevisiae deletion libraries in three genetic backgrounds resistant to statins, which are additional to the statin-sensitive S288C deletion library that has provided much of what is known about GINs in eukaryotes. Whole genome sequencing and linkage group analysis confirmed the genomic authenticity of the new deletion libraries. Statin response was probed by drug-gene interactions with atorvastatin and cerivastatin treatments, as well as gene-gene interactions with the statin target HMG1 and HMG2 genes or the sterol homeostatic ARV1 gene. The 20 GINs generated from these interactions were not conserved by function or topology across the four genetic backgrounds. Centrality measures and hierarchical agglomerative clustering identified master regulators that if removed collapsed the networks. Community structure distinguished a characteristic early secretory pathway pattern of gene usage in each genetic background. ER stress in statin-resistant backgrounds was buffered by protein folding genes, which was confirmed by reduced activation of the unfolded protein response in statin-resistant backgrounds relative to the statin-sensitive S288C background. These network analyses of new gene deletion libraries provide insight into the complexity of GINs underlying individual drug response.

systems biology↗